Aura Biosciences, Inc. (NASDAQ:AURA – Free Report) – Equities researchers at Lifesci Capital issued their Q3 2024 earnings per share (EPS) estimates for shares of Aura Biosciences in a research report issued on Monday, September 9th. Lifesci Capital analyst A. Dhankher anticipates that the company will earn ($0.42) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.71) per share. Lifesci Capital also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.65) EPS and FY2025 earnings at ($2.52) EPS.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.04.
Check Out Our Latest Stock Analysis on AURA
Aura Biosciences Trading Up 0.6 %
Shares of AURA stock opened at $9.07 on Thursday. Aura Biosciences has a 12-month low of $5.99 and a 12-month high of $12.35. The business’s fifty day simple moving average is $8.36 and its 200-day simple moving average is $7.85. The company has a market cap of $449.36 million, a PE ratio of -4.88 and a beta of 0.36.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Monashee Investment Management LLC purchased a new stake in Aura Biosciences in the fourth quarter valued at approximately $1,758,000. Franklin Resources Inc. purchased a new stake in shares of Aura Biosciences in the 4th quarter valued at $5,317,000. Platinum Investment Management Ltd. acquired a new stake in shares of Aura Biosciences in the fourth quarter worth $1,596,000. Levin Capital Strategies L.P. raised its holdings in shares of Aura Biosciences by 194.5% during the second quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after purchasing an additional 216,266 shares during the last quarter. Finally, Matrix Capital Management Company LP grew its position in Aura Biosciences by 29.1% during the 4th quarter. Matrix Capital Management Company LP now owns 6,922,870 shares of the company’s stock worth $61,337,000 after purchasing an additional 1,560,000 shares during the period. 96.75% of the stock is owned by institutional investors and hedge funds.
About Aura Biosciences
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Featured Stories
- Five stocks we like better than Aura Biosciences
- What is a buyback in stocks? A comprehensive guide for investors
- 4 Stocks to Watch as Analysts Adjust Their Expectations
- There Are Different Types of Stock To Invest In
- Super Micro’s Delayed Filing: A Warning or an Opportunity?
- 3 Small Caps With Big Return Potential
- 3 Key Reasons Why Rocket Companies Stock Will Rally Soon
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.